Stock Events

Stock Events

Search...

X.T.L. Biopharmaceuticals

€2.6

0

+€0+0% Today

Statistics

Day High

2.6

Day Low

2.6

52W High

-

52W Low

-

Volume

0

Avg. Volume

-

Mkt Cap

12.89M

P/E Ratio

-

Dividend Yield

-

Dividend

-

Earnings

14MarExpected

Q2 2022

Q3 2022

Q4 2022

Q1 2023

Q2 2023

Q3 2023

Q4 2023

-0.15

-0.1

-0.05

0

Expected EPS

0

Actual EPS

0

People Also Follow

This list is based on the watchlists of people on Stock Events who follow H2K2.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Gilead Sciences

Gilead Sciences is a biopharmaceutical company that develops and markets drugs in similar therapeutic areas as XTLB, including treatments for viral diseases.

Amgen focuses on human therapeutics and has developed products in areas that overlap with XTLB's research interests, such as immunology and inflammation.

Biogen develops therapies for neurological and neurodegenerative diseases, competing directly with XTLB's focus on autoimmune diseases and immunotherapy.

Vertex Pharmaceuticals

Vertex Pharmaceuticals concentrates on creating drugs for complex diseases, a similar approach to XTLB's focus on targeted therapeutic applications.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is known for its innovation in biopharmaceuticals, directly competing with XTLB in the field of biologic therapies.

Incyte specializes in oncology and inflammation, aligning closely with XTLB's research into immune response modulation.

Novartis is a global healthcare company that develops treatments across a broad range of areas, including those targeted by XTLB.

Pfizer operates across various therapeutic areas, including immunology and oncology, overlapping with XTLB's therapeutic development strategies.

About

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

Show more...

CEO

Mr. Shlomo Spokone Shalev

Country

US

ISIN

US98386D3070

WKN

000A2DK34

Listings